Haemonetics vs Lantheus
Add, change or remove companies; up to four.
The short version
- Lantheus is the larger business, with $1.5B of revenue in fiscal 2025 against $1.3B for Haemonetics.
- Lantheus grew revenue faster (0.5%, against −2.0%).
- Lantheus kept more of each dollar of sales as operating profit (20.2% operating margin, against 11.8%).
- Lantheus turned more of its sales into free cash flow (23.0% FCF margin, against 19.5%).
- Lantheus earned a higher return on the capital invested in it (22.7%, against 6.7%).
- Investors pay more for each dollar of Haemonetics’s earnings: a P/E of 57.3x against 24.2x for Lantheus.
| Latest fiscal year | HAE · FY26 | LNTH · FY25 |
|---|---|---|
| Size | ||
| Market cap | $5.4B | $6.7B |
| Revenue | $1.3B | $1.5B |
| Free cash flow | $260M | $354M |
| Net income | $97.3M | $234M |
| Growth | ||
| Revenue growth | −2.0% | 0.5% |
| 5-year growth | 8.9% | 35.4% |
| Share count change | −6.7% | −4.5% |
| Profitability | ||
| Gross margin | 59.0% | 61.1% |
| Operating margin | 11.8% | 20.2% |
| Net margin | 7.3% | 15.2% |
| FCF margin | 19.5% | 23.0% |
| Return on capital | 6.7% | 22.7% |
| Return on equity | 12.0% | 21.5% |
| Balance sheet | ||
| Net debt | $994M | $210M |
| Net debt / EBITDA | 3.7x | 0.6x |
| Dividends and buybacks | $175M | $300M |
| Valuation & quality | ||
| P/E | 57.3x | 24.2x |
| Piotroski F-score | 7 | 5 |
FY17
HAE $886M
LNTH $331M
FY18
HAE $904M
LNTH $343M
FY19
HAE $968M
LNTH $347M
FY20
HAE $989M
LNTH $339M
FY21
HAE $871M
LNTH $425M
FY22
HAE $993M
LNTH $935M
FY23
HAE $1.2B
LNTH $1.3B
FY24
HAE $1.3B
LNTH $1.5B
FY25
HAE $1.4B
LNTH $1.5B
FY26
HAE $1.3B
LNTH —
HAE
LNTH
FY17
HAE −2.2%
LNTH 15.7%
FY18
HAE 6.2%
LNTH 18.8%
FY19
HAE 8.6%
LNTH 14.9%
FY20
HAE 10.5%
LNTH −1.2%
FY21
HAE 10.3%
LNTH −14.3%
FY22
HAE 8.1%
LNTH 3.9%
FY23
HAE 13.4%
LNTH 28.1%
FY24
HAE 12.6%
LNTH 29.8%
FY25
HAE 16.3%
LNTH 20.2%
FY26
HAE 11.8%
LNTH —
HAE
LNTH
FY17
HAE $83.6M
LNTH $37.2M
FY18
HAE $146M
LNTH $41.1M
FY19
HAE $40.3M
LNTH $58.3M
FY20
HAE $109M
LNTH $16.4M
FY21
HAE $71.8M
LNTH $53.9M
FY22
HAE $75.8M
LNTH $21.8M
FY23
HAE $81.7M
LNTH $260M
FY24
HAE $144M
LNTH $493M
FY25
HAE $142M
LNTH $354M
FY26
HAE $260M
LNTH —
HAE
LNTH
FY17
HAE −1.6%
LNTH 30.9%
FY18
HAE 4.9%
LNTH 24.0%
FY19
HAE 7.5%
LNTH 23.5%
FY20
HAE 10.8%
LNTH −0.8%
FY21
HAE 8.6%
LNTH −8.0%
FY22
HAE 4.4%
LNTH 6.4%
FY23
HAE 9.9%
LNTH 46.2%
FY24
HAE 8.8%
LNTH 47.1%
FY25
HAE 10.5%
LNTH 22.7%
FY26
HAE 6.7%
LNTH —
HAE
LNTH
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.